Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Background
    • Rationale
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center

Dec 17 2020

Interim Analysis of Recardio’s Phase II Clinical Trial published in European Heart Journal

San Francisco, December 17, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio’s Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

Read More

Written by Recardio · Categorized: Uncategorized

Sep 14 2020

Study Protocol of Phase 2 Trial of Recardio Published in the Trials Journal BioMed Central

San Francisco, September 14, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the study protocol for its Clinical Phase 2 Study. Entitled “Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”, the article can be accessed here: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04652-0

Read More

Written by Recardio · Categorized: Uncategorized

Jun 29 2020

Interim Analysis of Recardio’s Phase II Clinical Trial to be Presented at the 2020 Congress of the European Society of Cardiology

San Francisco, June 29, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio’s Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29th through September 1st.

Read More

Written by Recardio · Categorized: Uncategorized

May 15 2020

Clinical Trial Outcomes of Recardio’s Dutogliptin Published in the British Journal of Pharmacology

San Francisco, May 15, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Read More

Written by Recardio · Categorized: Uncategorized

Feb 17 2020

Recardio Completes Interim Analysis of Phase 2 in AMI

San Francisco, February 17, 2020 – Recardio Inc., a clinical stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Read More

Written by Recardio · Categorized: Uncategorized

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2021 · All Rights Reserved

Copyright © 2021 · Recardio on Genesis Framework · WordPress · Log in